Mersana Therapeutics (MRSN) Insider Trading & Ownership $8.06 -0.15 (-1.77%) As of 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Mersana Therapeutics (NASDAQ:MRSN) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage13.00%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)5Amount OfInsider Selling(Last 12 Months)$43.16K Get MRSN Insider Trade Alerts Want to know when executives and insiders are buying or selling Mersana Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MRSN Insider Buying and Selling by Quarter Mersana Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/12/2025Martin H Jr. HuberCEOSell2,012$7.31$14,707.72 1/16/2025Anna ProtopapasDirectorSell345$14.50$5,002.50 1/16/2025Ashish MandeliaCAOSell142$14.50$2,059.00 1/16/2025Martin H Jr. HuberCEOSell180$14.50$2,610.00 1/16/2025Timothy B LowingerSVPSell321$14.50$4,654.50 1/14/2025Anna ProtopapasDirectorSell461$16.50$7,606.50 1/14/2025Ashish MandeliaCAOSell40$16.50$660.00 1/14/2025Timothy B LowingerSVPSell139$16.50$2,293.50 10/28/2024Mohan BalaSVPSell75$47.50$3,562.50 (Data available from 1/1/2013 forward) MRSN Insider Trading Activity - Frequently Asked Questions Who is on Mersana Therapeutics' Insider Roster? The list of insiders at Mersana Therapeutics includes Alejandra Carvajal, Anna Protopapas, Arvin Yang, Ashish Mandelia, Brian Deschuytner, Martin H Jr. Huber, Mohan Bala, Timothy B Lowinger, and Tushar Misra. Learn more on insiders at MRSN. What percentage of Mersana Therapeutics stock is owned by insiders? 13.00% of Mersana Therapeutics stock is owned by insiders. Learn more on MRSN's insider holdings. Which Mersana Therapeutics insiders have been selling company stock? The following insiders have sold MRSN shares in the last 24 months: Alejandra Carvajal ($10,927.00), Anna Protopapas ($92,215.25), Ashish Mandelia ($26,036.75), Brian Deschuytner ($41,420.75), Martin H Jr. Huber ($106,021.72), Mohan Bala ($5,709.50), Timothy B Lowinger ($6,948.00), and Tushar Misra ($9,078.50). How much insider selling is happening at Mersana Therapeutics? Insiders have sold a total of 8,430 Mersana Therapeutics shares in the last 24 months for a total of $298,357.47 sold. Mersana Therapeutics Key ExecutivesDr. Martin H. Huber M.D. (Age 63)President, CEO & Director Compensation: $44kMr. Brian C. DeSchuytner (Age 45)Senior VP, CFO & COO Compensation: $626.32kDr. Timothy B. Lowinger Ph.D. (Age 60)Senior VP and Chief Science & Technology Officer Compensation: $666.3kMs. Alejandra Veronica Carvajal J.D. (Age 50)Senior VP, Secretary & Chief Legal Officer Compensation: $606.51kMr. Mikhail Papisov Ph.D.Co-FounderMr. Ashish Mandelia (Age 49)VP, Controller & Chief Accounting Officer Mr. Jason FredetteSenior Vice President of Investor Relations & Corporate CommunicationsMr. Chuck MillerSenior Vice President of Regulatory AffairsMr. Marc DamelinExe. Director and Head of Biology, Oncology, Antibody-Drug Conjugate ADC Discovery & Develop.Dr. Tushar Misra Ph.D. (Age 63)Senior VP & Chief Manufacturing Officer Compensation: $485.89k More Insider Trading Tools from MarketBeat Related Companies CRBP Insider Trading BTMD Insider Trading NKTX Insider Trading SAVA Insider Trading CLYM Insider Trading AVTX Insider Trading GLSI Insider Trading CRDF Insider Trading IVVD Insider Trading KALA Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Marvell Insiders Buy Shares—Should Investors Follow Suit?Insider Sales Jump at Broadcom and CoreWeave: Red Flag Ahead?Oklo Insiders Sell! Oh No! This Is Why Investors Shouldn’t WorryTop Insider Buys and Sells From September: Buy, Sell, or Hold?NuScale, Rocket Lab Face Heavy Insider Selling After Surges This page (NASDAQ:MRSN) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mersana Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mersana Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
